FDA approves kallikrein inhibitor to treat hereditary angioedema

被引：27

|

作者：

Thompson, Cheryl A.

机构：

来源：

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY | 2010年 / 67卷 / 02期

关键词：

D O I：

10.2146/news100005

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

收藏

页码：93 / 93

页数：1

相关论文

共 50 条

[31] FDA approves Gleevec to treat gastrointestinal cancers
不详
[J]. LABORATORY MEDICINE, 2002, 33 (03) : 177 - 177
[32] FDA approves Tamiflu to treat young infants
[J]. Reactions Weekly, 2013, 1434 (1) : 3 - 3
[33] FDA approves hereditary blindness gene therapy
不详
[J]. NATURE BIOTECHNOLOGY, 2018, 36 (01) : 6 - 6
[34] FDA approves first telomerase inhibitor
Mullard, Asher
[J]. NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (08) : 570 - 570
[35] FDA approves first RET inhibitor
[J]. Nature Biotechnology, 2020, 38 (6) : 662 - 662
[36] The FDA approves a first farnesyltransferase inhibitor
Asher Mullard
[J]. Nature Reviews Drug Discovery, 2021, 20 : 8 - 8
[37] The FDA approves a first farnesyltransferase inhibitor
Mullard, Asher
[J]. NATURE REVIEWS DRUG DISCOVERY, 2021, 20 (01) : 8 - 8
[38] Use of recombinant plasma kallikrein inhibitor in hereditary angioedema: A case report and review of the management of the disorder
Turner, MD
Ougbourli, A
Heaney, K
Selvaggi, T
[J]. JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2004, 62 (12) : 1553 - 1556
[39] Plasma kallikrein activation in patients with hereditary angioedema due to C1 inhibitor deficiency
Zanichelli, A.
Maggioni, L.
Cicardi, M.
[J]. ALLERGY, 2009, 64 : 571 - 572
[40] Tissue kallikrein gene polymorphism and angioedema in patients with hereditary C1 inhibitor deficiency
Frémeaux-Bacchi, V
Guinnepain, MT
Weiss, L
Blouin, J
Laurent, J
Fridman, WH
[J]. MOLECULAR IMMUNOLOGY, 2006, 43 (1-2) : 164 - 164

← 1 2 3 4 5 →